



August 12, 2026

For Immediate Release

Company Name:	Sumitomo Chemical Co., Ltd.
Representative:	Nobuaki Mito Representative Director & President
Securities Code:	4005
Stock Exchange Listings:	Tokyo Stock Exchange Prime Market
Inquiries:	Shoko Wato General Manager Corporate Communications Dept. (Tel: +81-3-5201-0200)

Announcement Regarding Report on the Group

Sumitomo Chemical Co., Ltd. hereby announces that its subsidiary, Sumitomo Pharma Co., Ltd., today issued a statement entitled “Regarding a Report Concerning Sumitomo Pharma (The Company's Views on ‘Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns’).” For further details, please see the attachment.

Press Release

August 12, 2026

Sumitomo Pharma Co., Ltd.

**Regarding a Report Concerning Sumitomo Pharma (The Company's Views on
“Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA,
Dr. Yamanaka, and the undisclosed history of image duplication concerns”)**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; the “Company”) has confirmed that Gotham City Research LLC (“GCR”) published a report, “Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns” (the “August 7 Report”), concerning the Company on August 7, 2026.

The August 7 Report is based on GCR’s unilateral views and assertions, which are not acceptable to the Company. In addition, GCR discloses in the August 7 Report that it and its partner companies and related persons “hold short positions in the covered issuers’ stock and stand to profit in the event the covered issuer’s stock price declines.”

The August 7 Report contains statements regarding AMCHEPRY®, one of the Company’s products. AMCHEPRY® has been developed through many years of industry-academia-government collaboration with Kyoto University and other institutions. The Company has confirmed the reliability of the materials submitted for regulatory review of AMCHEPRY®, and AMCHEPRY® was granted conditional and time-limited approval following scientific and medical review and assessment by the relevant regulatory authorities.

In addition, in accordance with the conditions attached to the approval, the Company is appropriately conducting a post-marketing clinical study (Phase 4 study) and steadily accumulating further evidence regarding the efficacy and safety of AMCHEPRY®, with the aim of obtaining full approval as early as possible.

The Company will continue to provide timely and appropriate disclosures to its shareholders and investors.

The Company also notes that GCR published a report on August 3, 2026, containing unilateral views regarding the Company’s financial reporting. The Company will take appropriate action, including legal action where necessary, in response to inaccurate or misleading information in order to protect the interests of the Company and its shareholders and investors.

Contact:

Corporate Communications, Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp